{"id":"syr-472","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperphosphatemia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Stomatitis"}]},"_chembl":{"chemblId":"CHEMBL5885080","moleculeType":null,"molecularWeight":"547.62"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"SYR-472 targets FGFR pathways that are dysregulated in certain cancers, particularly those with FGFR gene fusions or amplifications. By inhibiting FGFR kinase activity, the drug suppresses proliferation of cancer cells driven by these molecular alterations. This mechanism is particularly relevant in solid tumors with specific FGFR genetic alterations.","oneSentence":"SYR-472 is a selective inhibitor of fibroblast growth factor receptor (FGFR) signaling that blocks aberrant growth signals in cells dependent on FGFR activation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:37:02.440Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Solid tumors with FGFR gene fusions or amplifications"}]},"trialDetails":[{"nctId":"NCT07073768","phase":"PHASE3","title":"Comparison Between Efficacy of Trelagliptin and Sitagliptin in Type II Diabetic Patients","status":"ENROLLING_BY_INVITATION","sponsor":"Khyber Medical College, Peshawar","startDate":"2025-07-01","conditions":"Diabetes Mellitus Type 2, Glycemic Control for Diabetes Mellitus","enrollment":126},{"nctId":"NCT06913101","phase":"NA","title":"Comparison of Once-Weekly Trelagliptin vs. Once-Daily Vildagliptin for HbA1c Reduction in Type 2 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"PNS Hafeez - Naval Hospital","startDate":"2024-11-15","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":102},{"nctId":"NCT06889909","phase":"NA","title":"Comparison of Once-Weekly Trelagliptin Vs. Once-Daily Vildagliptin for HbA1c Reduction in Type 2 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lahore General Hospital","startDate":"2024-12-15","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":102},{"nctId":"NCT04285983","phase":"","title":"Specified Drug-Use Survey of Trelagliptin Tablets \"Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Severe Renal Impairment or End-stage Renal Disease\"","status":"COMPLETED","sponsor":"Takeda","startDate":"2020-03-01","conditions":"Type 2 Diabetes Mellitus","enrollment":89},{"nctId":"NCT03231709","phase":"PHASE4","title":"Treatment Preference for Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Versus Daily DPP-4 Inhibitors in Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-08-18","conditions":"Type 2 Diabetes Mellitus","enrollment":60},{"nctId":"NCT02372097","phase":"PHASE1","title":"A Phase 1, Bioequivalence Study of SYR-472 25mg and 50mg Tablets","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-03","conditions":"Healthy","enrollment":24},{"nctId":"NCT03014479","phase":"PHASE4","title":"Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-02-18","conditions":"Type 2 Diabetes","enrollment":219},{"nctId":"NCT01431807","phase":"PHASE3","title":"Long-term Study of SYR-472","status":"COMPLETED","sponsor":"Takeda","startDate":"2011-09-01","conditions":"Diabetes Mellitus","enrollment":680},{"nctId":"NCT02324569","phase":"PHASE3","title":"A Phase 4, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 4, Open-label, Long-term Study of SYR-472 (100 mg) in Combination With Insulin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-12-27","conditions":"Type 2 Diabetes Mellitus","enrollment":240},{"nctId":"NCT02771093","phase":"PHASE4","title":"An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-09-08","conditions":"Type 2 Diabetes Mellitus","enrollment":27},{"nctId":"NCT03555591","phase":"","title":"Specified Drug-Use Survey of Trelagliptin Tablets \"Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus\"","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-05-01","conditions":"Type 2 Diabetes Mellitus","enrollment":3198},{"nctId":"NCT02512068","phase":"PHASE3","title":"A Phase 3, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 3, Multicenter, Open-label, Long-term Study of SYR-472 (25 mg) in Patients With Type 2 Diabetes Mellitus Complicated by Severe Renal Impairment or End-stage Renal Disease","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-08-07","conditions":"Type 2 Diabetes Mellitus","enrollment":107},{"nctId":"NCT01632007","phase":"PHASE3","title":"Double-blind Comparative Study of SYR-472","status":"COMPLETED","sponsor":"Takeda","startDate":"2012-05-01","conditions":"Diabetes Mellitus","enrollment":245},{"nctId":"NCT01751360","phase":"PHASE3","title":"SYR-472 Open-label Study","status":"COMPLETED","sponsor":"Takeda","startDate":"2013-04-01","conditions":"Diabetes Mellitus","enrollment":14},{"nctId":"NCT03940183","phase":"PHASE3","title":"Clinical Trial of Trelagliptin Succinate Tablets in the Treatment of Type 2 Diabetes","status":"COMPLETED","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2019-07-08","conditions":"Diabetes Mellitus, Type 2","enrollment":254},{"nctId":"NCT04374864","phase":"PHASE4","title":"Dose Modification Requirement for Trelagliptin in Egyptian Population","status":"UNKNOWN","sponsor":"British University In Egypt","startDate":"2020-03-01","conditions":"Diabetes Mellitus","enrollment":6},{"nctId":"NCT03362398","phase":"NA","title":"Omarigliptin & Trelagliptin in Twelve Healthy Egyptian Volunteers","status":"COMPLETED","sponsor":"British University In Egypt","startDate":"2017-11-20","conditions":"Diabetes Mellitus, Type 2","enrollment":12},{"nctId":"NCT00760344","phase":"PHASE2","title":"Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-03","conditions":"Diabetes Mellitus","enrollment":386},{"nctId":"NCT00653185","phase":"PHASE2","title":"Efficacy of SYR-472 in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-05","conditions":"Diabetes Mellitus","enrollment":369},{"nctId":"NCT02528019","phase":"PHASE4","title":"Metabolic and Cardiovascular Effects of Dipeptidyl Peptidase-4 (DPP-4) or Sodium-glucose Co-transporter Type 2 (SGLT2) Inhibitors","status":"UNKNOWN","sponsor":"Kurume University","startDate":"2015-08","conditions":"Effects of the DPP-4 Inhibitors or SGLT2 Inhibitors on the Protective Actions for Diabetic Complications","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SYR-472","genericName":"SYR-472","companyName":"Takeda","companyId":"takeda","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SYR-472 is a selective inhibitor of fibroblast growth factor receptor (FGFR) signaling that blocks aberrant growth signals in cells dependent on FGFR activation. Used for Solid tumors with FGFR gene fusions or amplifications.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":4,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}